Physicians to quickly initiate emergency interventions for patients who The anticoagulant effect of dabigatran within minutes, allowing “The RE-VERSE AD study has demonstrated that idarucizumab can reverse
Gastrointestinal (GI) bleeding and in those with a need for urgent They provideįurther insights on the use of idarucizumab in patients with Scientific Sessions 2017 in Anaheim, California, USA. The analyses were presented at the American Heart Association (AHA) Or procedure, such as an orthopedic, vascular or abdominal procedure. These include those with acute bleeding or requiring an urgent surgery In reversing the anticoagulant effect of dabigatran etexilate (marketedĪs Pradaxa ®) in patients in diverse emergency situations. The safety and efficacy of idarucizumab (marketed as Praxbind ®) Boehringer Ingelheim announced results from two sub-analyses of the
0 kommentar(er)
